Janus double-sided nanofibrous patch with asymmetric wettability and controlled topical delivery of tryptanthrin and indirubin as an effective therapy for psoriasis

Local side effects, such as skin dryness and irritation, present significant challenges for topical therapies for psoriasis. There is an urgent need for innovative and safer topical treatments, especially for individuals with mild to moderate psoriasis. In this study, we developed a double-sided Janus-structured nanofibrous patch characterized by asymmetric wettability, with the inner hydrophilic layer topped with a hydrophobic outer polycaprolactone (PCL) layer. The hydrophobic PCL layer functions to facilitate directional hydration through controlled water transport, while the hydrophilic inner layer containing two anti-psoriatic compounds, indirubin and tryptanthrin, ensures optimal anti-psoriasis efficacy. By coaxial electrospinning, the core of the hydrophilic layer contains hyaluronic acid (HA), polyethylene oxide (PEO) and indirubin, while the shell is composed of PCL, PEO, and tryptanthrin. Investigations into the release of anti-psoriatic compounds indicated that both indirubin and tryptanthrin were liberated in bursts. <i>In vitro</i> assessments using psoriatic skin from mice demonstrated notable skin retention and permeation of both compounds within the first 30 min following topical application. Further biological analyses confirmed favorable <i>in vitro</i> biocompatibility, supporting the anticipated therapeutic outcomes, as assessed by severity index scoring and pathological evaluations <i>in vivo</i>. Additionally, an initial human test demonstrated that the efficacy of the double-sided Janus-structured patch was comparable to that of the first-line drug Calcipotriol Ointment during a 4-week topical treatment, with no adverse effects like erythema or pruritus. The unique Janus-structured design effectively combines asymmetric wettability with potent anti-psoriatic ingredients, offering a novel and comprehensive approach to topical therapies for psoriasis.

Authors

Institutions

Publication Details

Journal
Materials Today Bio
Published
2025-05-01
DOI
https://doi.org/10.1016/j.mtbio.2025.101822
Citations
1
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.79
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Janus double-sided nanofibrous patch with asymmetric wettability and controlled topical delivery of tryptanthrin and indirubin as an effective therapy for psoriasis

Yaqi Yue, Hongjie Gao, Yilin Peng, Ping Song et al.
1 citations
Materials Today Bio
Advancements in Transdermal Drug Delivery
0.79
article

Janus double-sided nanofibrous patch with asymmetric wettability and controlled topical delivery of tryptanthrin and indirubin as an effective therapy for psoriasis

Yaqi Yue, Hongjie Gao, Yilin Peng, Ping Song, Pengyu Wang, Ning Li, Can Cao, Ruodan Xu, Yu Sun, Xuyao Dai
article en
1 citations

Abstract

Local side effects, such as skin dryness and irritation, present significant challenges for topical therapies for psoriasis. There is an urgent need for innovative and safer topical treatments, especially for individuals with mild to moderate psoriasis. In this study, we developed a double-sided Janus-structured nanofibrous patch characterized by asymmetric wettability, with the inner hydrophilic layer topped with a hydrophobic outer polycaprolactone (PCL) layer. The hydrophobic PCL layer functions to facilitate directional hydration through controlled water transport, while the hydrophilic inner layer containing two anti-psoriatic compounds, indirubin and tryptanthrin, ensures optimal anti-psoriasis efficacy. By coaxial electrospinning, the core of the hydrophilic layer contains hyaluronic acid (HA), polyethylene oxide (PEO) and indirubin, while the shell is composed of PCL, PEO, and tryptanthrin. Investigations into the release of anti-psoriatic compounds indicated that both indirubin and tryptanthrin were liberated in bursts. <i>In vitro</i> assessments using psoriatic skin from mice demonstrated notable skin retention and permeation of both compounds within the first 30 min following topical application. Further biological analyses confirmed favorable <i>in vitro</i> biocompatibility, supporting the anticipated therapeutic outcomes, as assessed by severity index scoring and pathological evaluations <i>in vivo</i>. Additionally, an initial human test demonstrated that the efficacy of the double-sided Janus-structured patch was comparable to that of the first-line drug Calcipotriol Ointment during a 4-week topical treatment, with no adverse effects like erythema or pruritus. The unique Janus-structured design effectively combines asymmetric wettability with potent anti-psoriatic ingredients, offering a novel and comprehensive approach to topical therapies for psoriasis.

Materials Today BioVol. 32
Zhejiang Chinese Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Xiyuan Hospital (CN)
Zero hunger
Openalex Percentile: Top 28%
Advancements in Transdermal Drug Delivery
0.79
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.